Oncology Brothers/X
Jun 4, 2024, 09:39
ASCO24 Day 4 Highlights by The Oncology Brothers
- The Oncology Brothers shared on X:
“ASCO24 Day 4 Highlights:
1. ICTAN: Adjuvant anti-EGFR duration in NSCLC
2. EV302: Ev plus Pembro HRQoL update in bladder cancer .
3. CM901 Update in bladder cancer
4. ABRAVE in TNBC
1. ICTAN:
- Phase III, n=251, adj icotinib for 6 or 12 months vs Obs in EGFR resected NSCLC
- 5 year OS: 74% and 74.5% vs. 65.1%
- Stage II 5 year DFS: 55.9% and 56.9% vs. 29.3%
- Stage III 5 year DFS: 45.1% and 47.5% vs. 21.9%
- What’s the right duration for Osi?
2. EV302:
- Enfortumab plus Pembro was approved in Dec 2023 for 1L mUC. Updated HRQoL
- Improvement in all functioning domains with EV 302
- Improved pain and QoL with EV302
3. CM901:
- Chemo plus Nivo was approved in March 2024 for 1L mUC. Update on LN only disease
- ~20% of the patients in this category
- 63% with CR and 18.5% with PR
- mOS: 46.3 months vs 24.9 months (HR: 0.58)
4. ABRAVE:
- Phase III, Adj Avelumab in TNBC after NACT
- Did not meet PFS end point but met OS secondary endpoint.
- 3 year OS 84.8% with Avelumab vs. 76.3% (HR 0.66)
- KN522 as SoC, how does this fit in?
- Importantly, who can we forego IO in adj (if pCR)?”
Source: Oncology Brothers/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14